Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope
about
Crystal structure of a 3B3 variantâ A broadly neutralizing HIV-1 scFv antibodyDiverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingBroad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine targetStructure of a V3-containing HIV-1 gp120 coreA large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitorsStructure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.GPI-anchored single chain Fv--an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike.Back to the future: covalent epitope-based HIV vaccine development.Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.Epitope mapping of M36, a human antibody domain with potent and broad HIV-1 inhibitory activity.An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site.Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibodyStability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approachA comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.Antigenic conservation and immunogenicity of the HIV coreceptor binding siteIncreased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralizationAn oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions.Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralizationAnalysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.HIV-2 neutralization by intact V3-specific Fab fragments.Peptides presenting the binding site of human CD4 for the HIV-1 envelope glycoprotein gp120.Mapping of discontinuous conformational epitopes by amide hydrogen/deuterium exchange mass spectrometry and computational docking.Glycosyl-phosphatidylinositol-Anchored Anti-HIV Env Single Chain Variable Fragments Interfere with HIV-1 Env Processing and Viral Infectivity.Phylogenetic divergence of CD47 interactions with human signal regulatory protein alpha reveals locus of species specificity. Implications for the binding site.
P2860
Q27657585-E653C1EE-04B7-47AC-95E4-0D79758952D4Q27675486-444D79D1-5977-4FC5-8CDC-B76931077CF8Q29547347-95458478-6D7E-4F61-9C35-A778729A6E6BQ29619014-9980273B-71F1-4430-8BED-5C13C09BFA77Q33483840-30DE70B8-8660-4A33-95CA-0C0354ACC8A3Q34045535-E9C35C8C-D82F-46B6-86C1-B75D7558853CQ34221625-284D664C-1874-4DE3-B573-BE536B225EF8Q34597300-870EB266-B510-4D6E-BE5F-69A163F64509Q34637968-77549C1F-2D2D-406E-A406-0A69317E4D2CQ34776841-1C1E8B98-0530-4DF9-B77F-34CCAC6D04A0Q35234289-AC6718FB-91B3-47EB-B9F6-71111A79530BQ35545957-10D78F54-2B43-4A81-8258-7E088E930DA1Q35764163-8B4E963F-A45D-46D7-8A10-33366780D74CQ36149102-28256FB8-1AF6-4C58-8A07-BD1DFCF3FEB3Q36403587-8BF9BC1B-B951-4716-A5AE-50C7B62FA313Q36496923-6D175499-89C6-4B21-B0A2-A4222E2D9ACDQ36837815-52F708D5-C3B4-4102-909E-B5B9083BD95AQ36924968-89B9D2CA-B87E-4119-A18D-8DFAA7249DD1Q37593222-F4A0FCD5-8951-41A6-9EE0-1F918E6E0BF4Q38098075-8E3FC18D-13B3-413F-9B87-FB509049ECAEQ39723388-F6B8D8BC-47BD-4BBC-A414-FC7379E5E710Q40147993-69F162BB-3AFD-4CCA-A0B6-3F82E003D11BQ41823383-5428DB6C-20AF-4BDE-B9C7-8B203D980E71Q41965065-E0D2BBE1-E787-4366-AC67-1595AC6068CFQ44703007-421ED1DE-1C9A-406E-A36D-95306611877EQ47555792-F3130B67-4D4C-4270-89D2-CA761FFAC224Q50708434-A7A046CD-D547-44A4-AAF4-6A1CE43584C6
P2860
Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Crystal structure of the broad ...... nd fine mapping of its epitope
@ast
Crystal structure of the broad ...... nd fine mapping of its epitope
@en
Crystal structure of the broad ...... nd fine mapping of its epitope
@nl
type
label
Crystal structure of the broad ...... nd fine mapping of its epitope
@ast
Crystal structure of the broad ...... nd fine mapping of its epitope
@en
Crystal structure of the broad ...... nd fine mapping of its epitope
@nl
prefLabel
Crystal structure of the broad ...... nd fine mapping of its epitope
@ast
Crystal structure of the broad ...... nd fine mapping of its epitope
@en
Crystal structure of the broad ...... nd fine mapping of its epitope
@nl
P2093
P356
P1433
P1476
Crystal structure of the broad ...... nd fine mapping of its epitope
@en
P2093
Claudio Vita
Dennis R Burton
Dimiter S Dimitrov
Loic Martin
Mei-Yun Zhang
Michelle Andrykovitch
Ralph Pantophlet
Ramalakshmi Darbha
Sanjay Phogat
P304
P356
10.1021/BI035323X
P407
P577
2004-02-01T00:00:00Z